Finoriq research workspace
Alector, Inc. (ALEC) SEC Filings & Filing Highlights
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the. Review ALEC SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Company
- Alector, Inc. (ALEC)
- Ticker
- ALEC
- Market Cap
- $159.3M
- Latest Price
- $1.435
- Industry
- Biotech & Pharma
Alector, Inc. (ALEC) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Alector, Inc. (ALEC).
| Event | Form | Date |
|---|---|---|
| Alector, Inc.: Agreement terminationAlector, Inc. (the “Company”) was developing the investigational progranulin-elevating monoclonal antibodies, latozinemab and nivisnebart,... | 8-K1.02 | 2026-07-08 |
| Elizabeth Garofalo, M.DOn June 17, 2026, Alector, Inc. (“Alector”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, Ale... | 8-K5.07 | 2026-06-17 |
| Alector, Inc.: Material agreementOn May 7, 2026, Alector, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowe... | 8-K1.01 | 2026-05-07 |
| Alector Reports First Quarter 2026 Financial Results and Provides Business UpdateAlector Reports First Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-07 |
| Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateAlector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 8-K2.02 | 2026-02-25 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.